Form 4: Amedisys Inc. Executive Nick Muscato Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Nick Muscato, Chief Strategy Officer of Amedisys Inc., reports the acquisition of 5,832 restricted stock units and the disposition of shares to cover tax obligations.
Summary
- On February 16, 2025, Nick Muscato, Chief Strategy Officer of Amedisys Inc., acquired 5,832 restricted stock units (RSUs).
- These RSUs represent a contingent right to receive one share of Amedisys Inc.'s common stock each.
- The RSUs will vest 25% on each of February 16, 2026, and February 16, 2027, and 50% on February 16, 2028, contingent upon continuous employment with the Issuer.
- Also on February 16, 2025, Muscato disposed of 651 shares of common stock at a price of $92.6 to cover tax obligations.
- Following these transactions, Muscato directly owns 36,010 shares of Amedisys Inc. common stock.
- Muscato also indirectly owns 212 shares through a 401(k) plan, based on a plan statement dated December 31, 2024.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs suggests confidence in the company's future, while the sale of shares to cover taxes is a routine transaction.
Positives
- The acquisition of RSUs indicates confidence in the company's future performance by aligning executive compensation with shareholder value.
Future Outlook
The vesting schedule of the RSUs provides a future incentive for the executive to remain with the company and contribute to its success.
Industry Context
Form 4 filings are routine disclosures for publicly traded companies and their executives, providing transparency into insider transactions. This filing indicates standard compensation practices for executives at Amedisys.
Stakeholder Impact
- The RSU grants align executive interests with those of shareholders, incentivizing long-term value creation.
Key Dates
| Date | Description |
|---|---|
| December 31, 2024 | Date of 401(k) plan statement used for reporting indirect ownership. |
| February 16, 2025 | Date of RSU acquisition and stock disposition. |
| February 16, 2026 | First vesting date for 25% of the RSUs. |
| February 16, 2027 | Second vesting date for 25% of the RSUs. |
| February 16, 2028 | Final vesting date for 50% of the RSUs. |
| February 19, 2025 | Date of signature for the Form 4 filing. |
Keywords
Amedisys, Insider Trading, Form 4, RSUs, Stock Options, Executive Compensation, Beneficial Ownership, Nick Muscato, Chief Strategy Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.